Skip to Content

Crizanlizumab use while Breastfeeding

Drugs containing Crizanlizumab: Adakveo

Medically reviewed by Drugs.com. Last updated on May 20, 2021.

Crizanlizumab Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available about crizanlizumab during breastfeeding. Because crizanlizumab is a large protein molecule with a molecular weight of about 146,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Until more data become available, crizanlizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Crizanlizumab

CAS Registry Number

1690318-25-2

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal, Humanized

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.